Cardio Diagnostics Holdings, Inc. (CDIO) company profile
Close on Nov 12, 2026Market cap $5.53MP/E –Yield –
About Cardio Diagnostics
In Vitro & In Vivo Diagnostic Substances, SIC 2835
Cardio Diagnostics Holdings, Inc. develops and commercializes artificial intelligence-driven, epigenetics-based clinical blood tests and platforms for cardiovascular disease. The company's core product offerings include Epi+Gen CHD, a test designed to assess the three-year risk of symptomatic coronary heart disease events, and PrecisionCHD, a test used to detect coronary heart disease alongside actionable clinical intelligence. In addition, the firm offers HeartRisk, a cardiovascular risk intelligence platform, and CardioInnovate360, a research-use-only tool supporting biopharmaceutical discovery and development. Its diagnostic solutions serve patients, healthcare providers, health systems, self-insured employers, and payors.
The company operates a laboratory facility designed for high-complexity testing in compliance with federal clinical laboratory standards. In addition to expanding its provider and channel partner relationships within the United States, it pursues international market opportunities, including commercial initiatives in India. Cardio Diagnostics Holdings is headquartered in Chicago, Illinois.
Summary of the business section of Cardio Diagnostics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Cardio Diagnostics Holdings, Inc.
- Headquarters
- Chicago, IL
- Address
- 311 W. Superior Street, Suite 444 60645
- Phone
- (855) 226-9991
- Website
- cdio.ai
- Employees
- 7, Dec 31, 2023
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Prager Metis CPAs, LLC, Hackensack, New Jersey
Stock & identifiers
- Ticker
- CDIO
- Other tickers
- CDIOW
- Former tickers
- MAAQ until Oct 31, 2022
- Exchange
- Nasdaq
- IPO date
- Nov 24, 2021
- Shares outstanding
- 3M, Aug 7, 2026
- Public float
- $5.80M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-30 reverse, May 13, 2025
- SEC CIK
- 1870144
- CUSIP
- 14159C202
- ISIN
- US14159C2026
- FIGI
- BBG013P0VV65
- Share class FIGI
- BBG013P0VV74
- LEI
- 529900E3UWQ6LHYRCK14
- EIN
- 87-0925574
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| James Intrater | Director | 71,596 |
| Peter K. Fung | Director | – |
| Wendy J. Betts | Director | – |
| Paul Frederick Burton | Director | 8,803 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Other | Total | vs. prior year |
|---|---|---|---|---|
| Meeshanthini V. Dogan CEO | $300.00K | $12.30K | $312.30K | -76% |
| Warren Hosseinion Chairman | $300.00K | – | $300.00K | -20% |
| Elisa Luqman CFO | $275.00K | – | $275.00K | -22% |
| Timur Dogan CTO | $250.00K | $10.30K | $260.30K | -66% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- Nov 24, 2021
- Offer price
- $10.00
- Securities offered
- 6,200,000
- Gross proceeds
- $62.00M
- Exchange
- Nasdaq
- First trading day
- Jan 14, 2022
- First-day close
- $9.82-1.8%
- Lock-up ends (est.)
- Jul 13, 2022
“We are offering 6,200,000 units at an offering price of $10.00 per unit.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of April 1, 2024, we had seven full-time employees and two part-time employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?